Cosmetics Development Marketing Packaging 
FDA Law Blog
MARCH 21, 2024
As readers of our blog know, MoCRA was a significant change to regulation of cosmetics. Now in the second year of implementation, companies have started noticing the consequences as FDA implements the new requirements and develops regulations and guidance. By John W.M.
XTalks
APRIL 26, 2021
The marker may soon be found on food and beverage products, pet food, dietary supplements, cosmetics and more. Future Market Insights predicted in 2019, prior to the onset of the COVID-19 pandemic, that the upcycled food industry was worth more than $46 billion, with an estimated compound annual growth rate (CAGR) of five percent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
NOVEMBER 16, 2021
Baumhardt provides counsel to medical device, in vitro diagnostic, and combination product manufacturers on a wide range of pre- and post-marketing regulatory topics. In the pre-market area, Ms. In the post-market area, Ms.
Cloudbyz
MAY 24, 2023
Consumer products companies constantly strive to develop superior products that meet the ever-evolving needs of their consumer base. This is where unified clinical trial management solutions come into the picture, enhancing efficiency, reducing time to market, and ensuring high-quality, scientifically validated consumer products.
pharmaphorum
OCTOBER 27, 2022
Websites – Companies can use appropriate search engine optimisation (SEO) and marketing tools to ensure that their websites are displayed high on the list of results for relevant key word searches. Therefore, companies are encouraged to establish a methodology for calculating fair market value rates. About the authors.
Cloudbyz
OCTOBER 19, 2023
The pharmaceutical industry plays a critical role in improving healthcare by developing and bringing new medicines to market. Clinical trials are the backbone of drug development, and managing these trials efficiently is paramount.
FDA Law Blog
FEBRUARY 16, 2023
With the Rx-to-OTC switch objective in mind, FDA took the “ unprecedented ” step of developing and testing a model drug facts label (DFL) for OTC naloxone and published a label comprehension study and model DFLs for naloxone administered via nasal spray and auto-injector in 2019. including a QR code that links to additional training).
Expert insights. Personalized for you.
64 
Let's personalize your content